Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 217

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Effects of Adalimumab Maintenance Therapy on Health-Related Quality of Life of Patients With Crohn's Disease: Patient-Reported Outcomes of the CHARM Trial

Loftus, Edward V., Feagan, Brian G., Colombel, Jean-Frédéric, Rubin, David T., Wu, Eric Q., Yu, Andrew P., Pollack, Paul F., Chao, Jingdong, Mulani, Parvez · 2008 · The American Journal of Gastroenterology

Abstract

OBJECTIVES: We evaluated the effects of adalimumab maintenance therapy on health-related quality of life (HRQOL) in patients with moderate to severe Crohn's disease. METHODS: In a Phase III, randomized, double-blind clinical trial (CHARM) of moderate to severe Crohn's disease patients, HRQOL outcomes were compared between the adalimumab maintenance treatment groups (every other week and weekly injection) and the adalimumab induction-only group. The Zung Self-Rating Depression Scale, functional assessment of chronic illness therapy (FACIT)-Fatigue, visual analog pain scales, Inflammatory Bowel Disease questionnaire (IBDQ), and Medical Outcomes Study 36-item Short Form Health Survey (SF-36) were analyzed for 499 randomized responders (a decrease of > or =70 points from baseline in the Crohn's Disease Activity Index [CDAI]) at baseline and weeks 4, 12, 26, and 56. RESULTS: CHARM patients' HRQOL was substantially impaired at baseline. Following a 4-week adalimumab induction therapy, patients experienced statistically significant improvements in all HRQOL measures (P < 0.0001). Compared with patients who were assigned to placebo after induction therapy, patients who continued adalimumab at 40 mg every other week maintenance therapy reported less depression (P < 0.01), fewer fatigue symptoms (P < 0.001), greater improvements in the IBDQ (P < 0.05), greater SF-36 physical component summary scores (P < 0.05), and less abdominal pain (P < 0.05) from weeks 12 to 56. They also had greater SF-36 mental component summary scores at week 56 (P < 0.05). Patients who continued adalimumab at 40-mg weekly maintenance therapy reported less depression and fewer fatigue symptoms at week 56, greater improvement in IBDQ, and less abdominal pain from weeks 12 to 56 (all P < 0.05 vs. placebo). CONCLUSIONS: Adalimumab maintenance therapy provided sustained improvements in HRQOL for patients with moderate to severe Crohn's disease through week 56.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1572-0241.2008.02175.x

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Research works printed but not linked: 22

  1. Munkholm, 1995, Disease activity courses in a regional cohort of Crohn's disease patients, Scand J Gastroenterol, 30, 699, 10.3109/00365529509096316 · DOI · Paper page
  2. Cohen, 2002, The quality of life in patients with Crohn's disease, Aliment Pharmacol Ther, 9, 1603, 10.1046/j.1365-2036.2002.01323.x · DOI · Paper page
  3. Wilson, 2004, Prevalence and outcomes of anemia in inflammatory bowel disease: A systematic review of the literature, Am J Med, 116, 44S, 10.1016/j.amjmed.2003.12.011 · DOI · Paper page
  4. Longobardi, 2003, Work losses related to inflammatory bowel disease in the United States: Results from the National Health Interview Survey, Am J Gastroenterol, 98, 1064
  5. Fuller-Thomson, 2006, Depression and inflammatory bowel disease: Findings from two nationally representative Canadian surveys, Inflamm Bowel Dis, 12, 697, 10.1097/00054725-200608000-00005 · DOI · Paper page
  6. Guyatt, 1989, A new measure of health status for clinical trials in inflammatory bowel disease, Gastroenterology, 96, 804, 10.1016/0016-5085(89)90905-0 · DOI · Paper page
  7. Rutgeerts, 2008, Certolizumab pegol, a monthly subcutaneously administered Fc-free anti-TNF alpha, improves health-related quality of life in patients with moderate to severe Crohn's disease, Int J Colorectal Dis, 23, 289, 10.1007/s00384-007-0395-7 · DOI
  8. Ware, 1992, The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection, Med Care, 30, 473, 10.1097/00005650-199206000-00002 · DOI · Paper page
  9. Feagan, 2003, The effects of infliximab maintenance therapy on health-related quality of life, Am J Gastroenterol, 98, 2232, 10.1111/j.1572-0241.2003.07674.x · DOI
  10. Colombel, 2007, Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: The CHARM trial, Gastroenterology, 132, 52, 10.1053/j.gastro.2006.11.041 · DOI · Paper page
  11. McDowell, 1996, Measuring health: A guide to rating scales and questionnaires
  12. Cella, 2002, Fatigue in cancer patients compared with fatigue in the general United States population, Cancer, 94, 2528, 10.1002/cncr.10245 · DOI · Paper page
  13. Webster, 2003, The functional assessment of chronic illness therapy (FACIT) measurement system: Properties, applications, and interpretation, Health Qual Life Outcomes, 1, 79, 10.1186/1477-7525-1-79 · DOI · Paper page
  14. Irvine, 1994, Quality of life: A valid and reliable measure of therapeutic efficacy in the treatment of inflammatory bowel disease, Gastroenterology, 106, 287, 10.1016/0016-5085(94)90585-1 · DOI · Paper page
  15. Pallis, 2004, The inflammatory bowel disease questionnaire: A review of its national validation studies, Inflamm Bowel Dis, 10, 261, 10.1097/00054725-200405000-00014 · DOI
  16. Irvine, 1999, Development and subsequent refinement of the inflammatory bowel disease questionnaire: A quality-of-life instrument for adult patients with inflammatory bowel disease, J Pediatr Gastroenterol Nutr, 28, S23, 10.1097/00005176-199904001-00003 · DOI · Paper page
  17. Gregor, 1997, An evaluation of utility measurement in Crohn's disease, Inflamm Bowel Dis, 3, 265, 10.1097/00054725-199712000-00004 · doi:10.1097/00054725-199712000-00004
  18. Brazier, 1992, Validating the SF-36 health survey questionnaire: New outcome measure for primary care, BMJ, 305, 160, 10.1136/bmj.305.6846.160 · DOI · Paper page
  19. Ware, 1998, The equivalence of SF-36 summary health scores estimated using standard and country-specific algorithms in 10 countries: Results from the IQOLA Project. International Quality of Life Assessment, J Clin Epidemiol, 51, 1167, 10.1016/S0895-4356(98)00108-5 · DOI · Paper page
  20. Kosinski, 2000, Determining minimally important changes in generic and disease-specific health related quality of life questionnaires in clinical trials of rheumatoid arthritis, Arthritis Rheum, 43, 1478, 10.1002/1529-0131(200007)43:7<1478::AID-ANR10>3.0.CO;2-M · DOI · Paper page
  21. Surtees, 2003, Functional health status, chronic medical conditions and disorders of mood, Br J Psychiatry, 183, 299, 10.1192/bjp.183.4.299 · DOI
  22. Patrick, 2003, Assessing the clinical significance of health-related quality of life (HRQOL) improvements in anaemic cancer patients receiving epoetin alfa, Eur J Cancer, 39, 335, 10.1016/S0959-8049(02)00628-7 · DOI

Cited by

See all 217

Metadata

Authors
Loftus, E. V., Feagan, B. G., Colombel, J.-F., Rubin, D. T., Wu, E. Q., Yu, A. P., Pollack, P. F., Chao, J., & Mulani, P.
Venue
The American Journal of Gastroenterology
Published
2008-12
Volume
103
Issue
12
Pages
3132-3141
ISSN
  • 0002-9270 (ISSN-L)
  • 1572-0241
OpenAlex
W2055211617
Cited by
217
References
1
FWCI
9.14
Type
journal article
Language
en
Update notices
erratum (2009-07-02)
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Effects of Adalimumab Maintenance Therapy on Health-Related Quality of Life of Patients With Crohn's Disease: Patient-Reported Outcomes of the CHARM Trial. https://app.cochat.ai/papers/10.1111/j.1572-0241.2008.02175.x
The paper
Loftus, E. V., Feagan, B. G., Colombel, J.-F., Rubin, D. T., Wu, E. Q., Yu, A. P., Pollack, P. F., Chao, J., & Mulani, P. (2008). Effects of Adalimumab Maintenance Therapy on Health-Related Quality of Life of Patients With Crohn's Disease: Patient-Reported Outcomes of the CHARM Trial. The American Journal of Gastroenterology. https://doi.org/10.1111/j.1572-0241.2008.02175.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.